Avalo Therapeutics Inc (AVTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avalo Therapeutics Inc (AVTX) has a cash flow conversion efficiency ratio of -0.179x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.36 Million) by net assets ($91.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Avalo Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Avalo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Avalo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Avalo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avalo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sight Sciences Inc
NASDAQ:SGHT
|
-0.136x |
|
Sovereign Metals Ltd
AU:SVM
|
-0.301x |
|
Atha Energy Corp.
V:SASK
|
0.006x |
|
TechTarget, Inc. Common Stock
NASDAQ:TTGT
|
-0.015x |
|
Valid Soluções S.A
SA:VLID3
|
0.074x |
|
Vuzix Corp Cmn Stk
NASDAQ:VUZI
|
-0.163x |
|
Mufin Green Finance Ltd
NSE:MUFIN
|
-0.302x |
|
Lang & Schwarz Aktiengesellschaft
XETRA:LUS1
|
1.103x |
Annual Cash Flow Conversion Efficiency for Avalo Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Avalo Therapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see AVTX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $133.03 Million | $-49.06 Million | -0.369x | +91.22% |
| 2023-12-31 | $7.30 Million | $-30.68 Million | -4.200x | -271.39% |
| 2022-12-31 | $-10.91 Million | $-26.75 Million | 2.451x | +179.80% |
| 2021-12-31 | $23.08 Million | $-70.89 Million | -3.071x | -86.09% |
| 2020-12-31 | $24.56 Million | $-40.54 Million | -1.650x | -81.10% |
| 2019-12-31 | $21.00 Million | $-19.13 Million | -0.911x | -509.13% |
| 2018-12-31 | $20.91 Million | $-3.13 Million | -0.150x | -133.29% |
| 2017-12-31 | $27.86 Million | $12.52 Million | 0.449x | +100.64% |
| 2016-12-31 | $207.00K | $-14.57 Million | -70.402x | -8963.27% |
| 2015-12-31 | $13.08 Million | $-10.16 Million | -0.777x | -231.80% |
| 2014-12-31 | $-26.33 Million | $-15.52 Million | 0.589x | -8.42% |
| 2013-12-31 | $-17.85 Million | $-11.49 Million | 0.644x | +158.73% |
| 2012-12-31 | $8.48 Million | $-9.29 Million | -1.096x | -- |
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its nam… Read more